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Summary Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an
120 h continuous infusion of rIL-2, 18 x 106 iu m-2 day followed by three injections of 5FU 600 mg m-2 at
weekly intervals. Entry criteria included no previous chemotherapy, ambulatory performance status, and a
measurable lesion. In most cases side effects were easily manageable and only one patient required transfer to
an intensive care unit with the capillary leak syndrome. In three patients persistent hypotension was found to
be unrelated to treatment with rIL-2, being caused respectively by a line infection, pulmonary embolus, and
bowel perforation. This last proved a fatal complication. Five patients (33%; [95% confidence limits,
11.8%-61.6%]) achieved a partial response, and two non-responders later achieved a partial response when
treated with weekly 5FU. This regimen is currently being evaluated in a phase-III randomised controlled trial.
The median survival for patients with metastatic colorectal
cancer is 8 to 11 months (Morris et al., 1977). Five
fluorouracil (5FU) has been the mainstay of chemotherapy
for this cancer since its development 30 years ago. Although
objective responses are seen in 15% to 20% of cases, com-
plete responses are rare and there is no improvement in
survival (Moertel & Thynne, 1982).
Initial clinical studies with recombinant interleukin-2 (rIL-
2) were sponsored by the United States National Cancer
Institute using Cetus rIL-2 given as 8 hourly boluses together
with lymphokine activated killer cells. Partial responses were
seen in 3/9 patients with colorectal cancer (Rosenberg et al.,
1985) but toxicity was severe. West et al. (1987) used con-
tinuous infusions of rIL-2 in 13 patients with colorectal
cancer. Although, as predicted, toxicity was less than with
bolus injections, none of the patients responded.
In this study an attempt has been made to evaluate the
toxicity and response rate of rIL-2 infusions with sequential
SFU chemotherapy in patients with previously untreated
metastatic or unresectable colorectal cancer.
Patients and methods
Patients
Between January 1st 1988 and December 31st 1989 16
patients were entered into the study. All met the following
criteria: histologically documented evidence of metastatic or
unresectable colorectal carcinoma (Dukes C or D), meas-
urable progressive disease, no prior chemotherapy, radio-
therapy or immunotherapy, ambulatory performance status
(ECOG 0-1, Karnofsky 80% or more), WBC>4 x I091',
platelets> 100 x I09 l- 1, Hct> 30%, serum creatinine, serum
bilirubin, prothrombin time and activated partial thrombo-
plastin time within the normal range. None of the patients
had a significant history or current evidence of cardiac
disease, none had an infection requiring antibiotics, contrain-
dications to pressor agents, evidence of CNS metastases,
prior or second malignancies, organ allografts or the need for
treatment with corticosteroids.
All patients gave written informed consent to the study
which was approved by the Ethical Committee of the East
Dorset District Health Authority.
Demographic details of the patients are given in Table I.
Treatmentplan
Infusions of rIL-2 (EuroCetus B.V., Amsterdam, The Nether-
lands) were given through a central venous catheter in a dose
of 18 x 106 iu m-2 day over 120 h to patients nursed in a
ordinary oncology ward. Following this initial 5 days
patients were rested for 48 h, and then as outpatients
received 5FU 600 mg-2 by i.v. push, repeated twice at weekly
intervals. One week after the third injection of 5FU a second
cycle of treatment was begun. After this the patient was
reassessed. Patients with stable disease or better received two
further cycles of treatment and were then reassessed. Patients
obtaining a partial response or better, received two further
cycles (making a total of six). Patients with progressive
disease at any time after the first cycle, or who experienced
unacceptable toxicity, could be withdrawn from the study.
The infusion of rIL-2 was interrupted if any of the follow-
ing toxicities occurred: severe hypotension, cardiac arrhyth-
mia, myocardial ischaemia, agitation or confusion, serum
bilirubin >5mgdl-', serum creatinine>4.5mgdl-', bac-
terial sepsis, dyspnoea at rest, or prolongation of the pro-
thrombin time by 3 s or the activated partial time by 10 s
above controls.
Criteriafor response
Response was assessed by comparing images obtained by
X-ray, computerised tomography or ultrasound scan. In all
TableI Demographiccharacteristics ofpatientstreatedwith rIL-2and
5FU
No. ofpatients
Eligible
Evaluable
Age
Median (range)
M:F
Primary
Colon
Rectum
Site of metastases
Liver
Lung
Lymph node
Other abdominal
Months from diagnosis to first metastasis
Median (range)
Months from first metastasis to treatment
Median (range)
16
15
61 (44-77)
12:4
15
1
14
2
2
4
8 (0-65)
1 (0-50)
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cases the images were compared by the same radiologist
(J.S.). Complete response (CR) was defined as the disap-
pearance of all known disease determined by two observa-
tions not less than 4 weeks apart. Partial response (PR) was
defined as a 50% or greater decrease in size of all measurable
lesions (as determined by the product of the longest diameter
and the greatest perpendicular diameter) determined by two
observations not less than 4 weeks apart. Progressive disease
(PD) was defined as a greater than 25% increase in size of
any measurable lesion, or the appearance of any new lesions
not recognised previously. Stable disease (SD) was defined as
an improvement less than PR or a progression less than PD.
Results
Toxicity
Eleven patients were able to complete their designated
number of courses of treatment. Three out of five patients
achieving PR received six courses, four out of five patients
with SD received four courses, and four out of five patients
with PD received two courses.
One patient who had achieved a PR sustained a pul-
monary embolus after his fourth course and received no
further courses. Another patient in PR suffered from the
capillary leak syndrome during the fourth course and dec-
lined further therapy. One patient with SD suffered a pul-
monary embolus during the first round of rIL-2, and although
she received the 5 FU to complete her first course of treat-
ment, she declined further rIL-2. One patient died of progres-
sive disease at the end of his second course of rIL-2 and did
not complete his second course of therapy. One patient died
of a perforated bowel during his first course of rIL-2.
Interruption of rIL-2 infusion was required in 13 out of 54
courses, usually for hypotension. Nine patients received
100% of the prescribed rIL-2. The remaining six received
99%, 98%, 83%, 75% and 70% respectively. No dose reduc-
tions were required for 5 FU.
The range and severity of side effects are shown in Table
II. The usual systemic side effects of anorexia, pyrexia, rigors,
fatigue and malaise were seen in all patients, but were seldom
severe enough to require more than symptomatic treatment.
Six patients complained of a mild to moderately itchy
erythematous rash associated with dry itchy eyes.
Evidence of the capillary leak syndrome was minimal with
this approach. Only one patient experienced a weight gain of
more than 5%, and he required transfer to an intensive care
unit for dyspnoea and hypotension which were slow in res-
ponding to stopping the rIL-2 and the administration of
colloids and doapmine. When he arrived there, her recovered
rapidly without further therapeutic intervention. This patient
who became confused and hallucinatory was the only one to
suffer neuropsychiatric side effects.
A degree of hypotension occurred in all patients but it was
not usually severe and responded to the interruption of the
rIL-2 infusion. In three patients profound hypotension occur-
red during rIL-2 administration but did not respond to its
Table II Side effects of rIL-2
WHO score
Side effect 0 1 2 3 4
Malaise 0 13 2 1 0
Fatigue 0 13 2 1 0
Rigor 0 10 6 0 0
Rash 10 0 4 2 0
Diarrhoea 7 2 5 2 0
Vomiting 12 1 3 0 0
Fever 1 5 10 0 0
Hypotension 0 0 6 9 1
Thrombocytopenia 10 2 2 1 1
Anaemia 4 5 7 0 0
Raise serum creatinine 5 5 4 1 0
interruption, nor to the administration of colloid or pressor
agents. In the first patient the hypotension was caused by
perforation of the colon at the site of the unresectable car-
cinoma. This patient died from peritonitis. The second
patient suffered a pulmonary embolism during the infusion of
rIL-2, but subsequently made a full recovery on anti-
coagulant therapy. She declined further courses of rIL-2. The
third patient proved to have a central line infection with
staphylococcus epidermidis and responded to treatment with
vancomycin.
A degree of oliguria was common place, but only one
patient during one course had a WHO grade 3 rise in serum
creatinine, and this was in part due to the line infection
mentioned above.
Diarrhoea was reported as a problem during eight courses
of rIL-2. It was seldom serious but proved difficult to control
with codeine phosphate, loperamide or diphenoxylate. Apart
from the patient mentioned above two other patients suffered
pulmonary emboli, in both cases after the end of this study.
Haematological toxicity was mild despite the combination
of a marrow suppressive cytotoxic agent with the rIL-2. One
patient had WHO grade 4 thrombocytopenia during his third
and fourth courses of rIL-2 and required platelet trans-
fusions. Red cell transfusions were required on three
occasions.
Responses
One patient died from a perforated bowel during the first
course of rIL-2. Post mortem examination showed necrosis
of the tumour at the site of perforation, but this patient was
graded as unevaluable.
Of the 15 evaluable patients, five achieved PR (33%; [95%
confidence limits: 11.8-61.6%]), five had SD and five had
PD. The relationship between the responses and the courses
of treatment is shown in Table III. Tumour sites responding
to this treatment included liver, lung, lymph nodes and
colon. One patient had massive hepatic enlargement with
multiple metastases, the largest of which measured 36.6 cm2.
After treatment this tumour shrank to 4.5 cm2 and the liver
became impalpable. Serum carcinoembryonic antigen fell
from 6006 iu l-l to 264 iu '-l and serum alkaline phosphatase
from 868 iu -' to 145 iu -'. The patient's weight increased
from 69.4 kg before treatment to 78.7 kg at the end of six
courses. Another patient presented with nine measurable
metastases in her liver with a total area of 84.3 cm2 and a
pelvic mass of 77.5 cm2. After six courses of treatment all
hepatic masses had disappeared and the pelvic mass had
shrunk to 5.7cm2. Her weight rose from 95 kg to 123 kg.
Other responders achieved respectively 54.1%, 67.9% and
80.7% reductions in the size of masses in liver, liver and
lung, and liver and abdominal masses. Figure 1 shows chest
X-rays taken before and after six courses of treatment in one
Table III Disease status after individual courses in each patient
Course number
Patient 1 2 3 4 5 6
1 NE
2 SD SD SD SD
3 SD SD SD SD
4 SD SD PR PR PR PR
5 SD
6 SD SD SD SD
7 SD PR PR PR
8 SD SD SD SD
9 PD PD
10 PD PD
11 PD PD
12 SD PR PR PR PR PR
13 SD PD
14 PR PR PR PR
15 SD PR PR PR PR PR
16 PD PD1188 T.J. HAMBLIN et al.
a
b
Figure 1 Chest radiographs before and after six courses of treatment in patient number 12.
of these patients, showing reduction in the size of lung
metastases.
At the completion of the study patients were offered treat-
ment with 5FU 600 mg m-2 weekly. Two patient took up this
option, and one with SD and one with PD eventually
achieved PR. None of the other patients showed any further
improvement.
The median survival of the 15 evaluable patients was 476
days.
Discussion
This study confirms the observation of West et al. (1987) that
rIL-2 may be given by continuous intravenous infusion with
side effects that are manageable by discontinuing the
infusion. It draws attention to the fact that when hypoten-
sion persists following the interruption of the infusion then
another cause should be sought; in this series line infection,
pulmonary embolus and perforation of the bowel were im-
plicated. This latter complication has been previously
reported (Schwartzentruber et al., 1988).
The partial response rate seen in these patients of 33%, is
greater than seen with 5FU alone (Moertel & Thynne, 1982)
and of the order seen with 5FU and folinic acid (Petrelli et
al., 1987; Erlichman et al., 1988; Gastrointestinal Tumour
Study Group, 1989; Poon et al., 1989; Valone et al., 1989).
However, small numbers can be misleading and the 95%
confidence limits of 11.8%-61.6% suggest that it is well
within the bounds of possibility that such a response might
have occurred with 5 FU alone. Response to this drug mayINTERLEUKIN-2 AND FLUOROURACIL IN COLORECTAL CANCER 1189
be delayed and difficult to evaluate, as was demonstrated by
the two patients who responded to weekly 5 FU after failing
to respond to the combination. If the entire responses of the
seven patients in this study who achieved a partial response
were due to 5 FU alone then perhaps this drug has been
undervalued in the past.
Information from other phase II trials of rIL-2 and 5FU in
colorectal cancer is sparse. Reid et al. (1992) reported a 10%
response rate in a low toxicity regimen. Franks et al. (1993)
have reported some in-house EuroCetus data: in a series of
19 patients in whom rIL-2 and 5 FU were given in a different
order to that reported here, there were no responders. It is
clear from examining these two reports that they refer to the
same trial at different stages of maturation. Finally, Lopez et
al. (1991) have reported preliminary results of the combina-
tion of rIL-2, 5 FU, folinic acid and thymopentin in meta-
static colorectal cancer. Four out ofeight patients responded.
The value of rIL-2 in colorectal cancer is currently being
tested in a phase III randomised controlled trial of 5 FU and
folinic acid with and without rIL-2. An interim analysis of
this trial has appeared in abstract form. One hundred and
thirty-five patients were randomised, and the overall response
rate was 16% in the rIL-2 arm and 12% in the control arm
(Eremin et al., 1993). Further analysis of this trial is awaited.
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